A novel inhaled dry-powder formulation of ribavirin allows for efficient lung delivery in healthy participants and those with COPD in a Phase 1 study.

A novel inhaled dry-powder formulation of ribavirin allows for efficient lung delivery in healthy participants and those with COPD in a Phase 1 study. Antimicrob Agents Chemother. 2020 Feb 18;: Authors: Dumont E, Oliver A, Ioannou C, Billiard J, Dennison J, Van Den Berg F, Yang S, Chandrasekaran V, Young G, Lahiry A, Starbuck D, Harrell A, Georgiou A, Hopchet N, Gillies A, Baker S Abstract Chronic Obstructive Pulmonary Disease (COPD) is an inflammatory lung condition, causing progressive decline in lung function leading to premature death. Acute exacerbations in COPD patients are predominantly associated with respiratory viruses. Ribavirin is a generic broad-spectrum antiviral agent for treatment of respiratory infections in COPD. Using the Particle Replication In Non-wetting Templates (PRINT) technology, which produces dry-powder particles of uniform shape and size, two new inhaled formulations of ribavirin (Ribavirin-PRINT-CFI and Ribavirin-PRINT-IP) were developed for efficient delivery to the lung and to minimize bystander exposure. Ribavirin-PRINT-CFI was well tolerated in healthy participants after singles dosing and Ribavirin-PRINT-IP was well tolerated in healthy and COPD participants single and repeat dosing. Ribavirin-PRINT-CFI was replaced with Ribavirin-PRINT-IP as the latter formulation was found to have improved physicochemical properties and it had a higher ratio of active drug to excipient per unit dose. Ribavirin con...
Source: Antimicrobial Agents and Chemotherapy - Category: Microbiology Authors: Tags: Antimicrob Agents Chemother Source Type: research